DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NAMENDA

Summary for Tradename: NAMENDA

Patents:8
Applicants:1
NDAs:3
Suppliers: see list7
2013 Sales:$1,856,822,000
drug
patent expirations by year for
 NAMENDA

Pharmacology for Tradename: NAMENDA

Clinical Trials for: NAMENDA

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Status: Recruiting Condition: Epilepsy

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury
Status: Terminated Condition: Traumatic Brain Injury

A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Status: Active, not recruiting Condition: Autism Spectrum Disorders

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Memantine and Intensive Speech-Language Therapy in Aphasia
Status: Completed Condition: Aphasia; Stroke

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
Status: Completed Condition: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder

Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy
Status: Withdrawn Condition: Epilepsy

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Status: Completed Condition: Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Status: Not yet recruiting Condition: Major Depressive Disorder

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
Status: Completed Condition: Alzheimer Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs
NAMENDA
memantine hydrochloride
SOLUTION;ORAL021627Apr 18, 2005RXYes5,061,703*PED<disabled>Y<disabled>
Forest Labs
NAMENDA
memantine hydrochloride
TABLET;ORAL021487Oct 16, 2003DISCNNo5,061,703*PED<disabled>Y<disabled>
Forest Labs
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525Jun 21, 2010RXNo<disabled><disabled>
Forest Labs
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525Jun 21, 2010RXNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NAMENDA

Drugname Dosage Strength RLD Submissiondate
memantine hydrochlorideTablets5 mg and 10 mgNamenda10/16/2007
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNamenda XR6/10/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mgNamenda XR6/17/2013
memantine hydrochlorideExtended-release Capsules28 mgNamenda XR6/12/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNamenda XR8/16/2013

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc